These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23983047)

  • 21. Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule.
    Drescher CW; Shah C; Thorpe J; O'Briant K; Anderson GL; Berg CD; Urban N; McIntosh MW
    J Clin Oncol; 2013 Jan; 31(3):387-92. PubMed ID: 23248253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
    Yang WL; Gentry-Maharaj A; Simmons A; Ryan A; Fourkala EO; Lu Z; Baggerly KA; Zhao Y; Lu KH; Bowtell D; Jacobs I; Skates SJ; He WW; Menon U; Bast RC;
    Clin Cancer Res; 2017 Oct; 23(19):5912-5922. PubMed ID: 28637689
    [No Abstract]   [Full Text] [Related]  

  • 23. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective.
    Woodward ER; Sleightholme HV; Considine AM; Williamson S; McHugo JM; Cruger DG
    BJOG; 2007 Dec; 114(12):1500-9. PubMed ID: 17903229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2000 Feb; 107(2):165-9. PubMed ID: 10688498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
    Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC
    Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Menon U; McGuire AJ; Raikou M; Ryan A; Davies SK; Burnell M; Gentry-Maharaj A; Kalsi JK; Singh N; Amso NN; Cruickshank D; Dobbs S; Godfrey K; Herod J; Leeson S; Mould T; Murdoch J; Oram D; Scott I; Seif MW; Williamson K; Woolas R; Fallowfield L; Campbell S; Skates SJ; Parmar M; Jacobs IJ
    Br J Cancer; 2017 Aug; 117(5):619-627. PubMed ID: 28742794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening.
    Drescher CW; Nelson J; Peacock S; Andersen MR; McIntosh MW; Urban N
    Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):600-6. PubMed ID: 15066925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.
    Gu Z; He Y; Zhang Y; Chen M; Song K; Huang Y; Li Q; Di W
    J Transl Med; 2018 May; 16(1):114. PubMed ID: 29716620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL; Wang CJ; Qi P; Zhang YX
    Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.
    van Nagell JR; DePriest PD; Reedy MB; Gallion HH; Ueland FR; Pavlik EJ; Kryscio RJ
    Gynecol Oncol; 2000 Jun; 77(3):350-6. PubMed ID: 10831341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation.
    Menon U; Talaat A; Jeyarajah AR; Rosenthal AN; MacDonald ND; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    Br J Cancer; 1999 Jul; 80(10):1644-7. PubMed ID: 10408412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of transvaginal ultrasound in screening for ovarian cancer.
    Campbell S; Gentry-Maharaj A
    Climacteric; 2018 Jun; 21(3):221-226. PubMed ID: 29490504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Personalizing CA125 levels for ovarian cancer screening.
    Dorigo O; Berek JS
    Cancer Prev Res (Phila); 2011 Sep; 4(9):1356-9. PubMed ID: 21893498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life.
    Hensley ML; Robson ME; Kauff ND; Korytowsky B; Castiel M; Ostroff J; Hurley K; Hann LE; Colon J; Spriggs D
    Gynecol Oncol; 2003 Jun; 89(3):440-6. PubMed ID: 12798709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening.
    Drescher CW; Hawley S; Thorpe JD; Marticke S; McIntosh M; Gambhir SS; Urban N
    Cancer Prev Res (Phila); 2012 Aug; 5(8):1015-24. PubMed ID: 22750949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of ovarian cancer among women with a CA125 level of 35 U/ml or less.
    Kobayashi H; Yamada Y; Sado T; Sakata M; Yoshida S; Kawaguchi R; Kanayama S; Shigetomi H; Haruta S; Tsuji Y; Ueda S; Kitanaka T; Oi H
    Gynecol Obstet Invest; 2008; 65(2):133-8. PubMed ID: 17957102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
    Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
    Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses.
    Pitta Dda R; Sarian LO; Barreta A; Campos EA; Andrade LL; Fachini AM; Campbell LM; Derchain S
    BMC Cancer; 2013 Sep; 13():423. PubMed ID: 24044637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.